Please assess the completion status of the following clinical trial:

Trial Title: Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Essential hypertension not controlled at 5 mg bisoprolol or 5 mg amlodipine at least 4 weeks (definition of not controlled: SBP greater than or equal to (\>=) 140 millimeter of mercury (mmHg) with or without DBP \>= 90 mmHg)~* Male or female subjects \>=18 years of age, without limitation on race~* Medically accepted effective contraception if procreative potential exists (applicable for both male and female subjects until at least 90 days after the last dose of trial treatment)~* Subjects who have signed the informed consent form before any trial related assessment~Exclusion Criteria:~* General contraindications of beta-blockers and/or calcium channel blockers~  * Previous and concurrent acute heart failure or during episodes of heart failure decompensation requiring intravenous inotropic therapy~ * Concurrent cardiogenic shock~ * Previous and concurrent second or third degree atrioventricular (AV) block (without a pacemaker)~ * Previous and concurrent sick sinus syndrome~ * Previous and concurrent sinoatrial block~ * Concurrent symptomatic bradycardia~ * Concurrent symptomatic hypotension~ * Previous and concurrent severe bronchial asthma or chronic obstructive pulmonary diseases~ * Previous and concurrent severe peripheral arterial occlusive diseases and Raynaud's syndrome~ * Untreated pheochromocytoma~ * Concurrent metabolic acidosis~ * Known hypersensitivity to bisoprolol, amlodipine, dihydropyridine derivates or to any of the excipients~* Seated pulse rate less than 60 beats per minute (bpm) at screening~* Any other anti-hypertensive drugs (other than bisoprolol and amlodipine) are used within 4 weeks prior to the screening visit~* Use of any enzyme-modifying drugs acting on cytochrome P450 (CYP) 3A4 enzymes via inhibition (such as ketoconazole, itraconazole, ritonavir) or induction (such as rifampicin or hypericum perforatum) within 28 days before Day 1 of the trial~* Other significant disease that in the Investigator's opinion that would exclude the subject from the trial, such as uncontrolled diabetes mellitus, severe liver and/or kidney dysfunction, decompensated cardiac failure~* Any other condition or therapy which in the Investigator's opinion would pose a risk to the subject or interfere with the trial objectives~* Concurrent alcohol and/or drug abuse~* Known hypersensitivity to the trial treatments~* Pregnancy and lactation period. All female subjects with reproductive potential must have a negative pregnancy serum test within the 7 days prior to enrollment~* Known lack of subject compliance~* Legal incapacity or limited legal capacity~* Participation in another clinical trial within the previous 30 days~* Persons directly involved in the execution of the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bisoprolol failed group (Type: EXPERIMENTAL): Subjects who failed monotherapy with bisoprolol 5 milligram (mg) before trial inclusion will be randomized to bisoprolol failed group to receive Bisoprolol/Amlodipine FDC tablet
- Amlodipine failed group (Type: EXPERIMENTAL): Subjects who failed monotherapy with amlodipine 5 mg before trial inclusion will be randomized to amlodipine failed group to receive Bisoprolol/Amlodipine FDC tablet.

Based on this trial design, predict the completion outcome and termination type (if applicable).